Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

about

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.

P2860

Q47693093-0E563D67-855F-4C34-AC09-D567F9366B30

P2860

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

Item

http://www.wikidata.org/entity/Q47692217

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@en

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@nl

type

Item

label

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@en

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@nl

prefLabel

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@en

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@nl

P1476

Desvenlafaxine Versus Placebo ...... ith Major Depressive Disorder.

@en

P2093

Dalia B Wajsbrot

http://www.w3.org/2001/XMLSchema#string

Deborah Chiles

http://www.w3.org/2001/XMLSchema#string

Karen L Weihs

http://www.w3.org/2001/XMLSchema#string

Richard D England

http://www.w3.org/2001/XMLSchema#string

Richat Abbas

http://www.w3.org/2001/XMLSchema#string

Sara Ramaker

http://www.w3.org/2001/XMLSchema#string

William Murphy

http://www.w3.org/2001/XMLSchema#string

P2860

Antidepressant drug effects and depression severity: a patient-level meta-analysis

Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions

An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder

Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.

An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder.

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.

A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder

A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

P304

36-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/CAP.2017.0100

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29189044

http://www.w3.org/2001/XMLSchema#string

P921

placebo

P932

5771543

http://www.w3.org/2001/XMLSchema#string

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

about

P2860

P2860

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932